A randomized controlled trial protocol assessing the effectiveness, safety and cost-effectiveness of methotrexatevs. ciclosporin in the treatment of severe atopic eczema in children: the TREatment of severe Atopic eczema Trial (TREAT)

Irvine, A D, Jones, A P, Beattie, P, Baron, S, Browne, F, Ashoor, F, O'Neill, L, Rosala‐Hallas, A, Sach, T, Spowart, C, Taams, L, Walker, C, Wan, M, Webb, N, Williamson, P, Flohr, C and , The TREAT Trial Investigators (2018) A randomized controlled trial protocol assessing the effectiveness, safety and cost-effectiveness of methotrexatevs. ciclosporin in the treatment of severe atopic eczema in children: the TREatment of severe Atopic eczema Trial (TREAT). British Journal of Dermatology, 179 (6). pp. 1297-1306. ISSN 0007-0963

[img]
Preview
PDF (Accepted manuscript) - Submitted Version
Available under License Creative Commons Attribution Non-commercial.

Download (1MB) | Preview
[img]
Preview
PDF (Accepted_Manuscript) - Submitted Version
Download (1MB) | Preview

Abstract

Background: Oral systemic immuno‐modulatory medication is regularly used off‐licence in children with severe atopic eczema. However, there is no firm evidence regarding the effectiveness, safety, cost‐effectiveness and impact on quality of life from an adequately powered randomised controlled trial (RCT) using systemic medication in children. Patients/Methods: Multi‐centre, parallel group, assessor‐blind, pragmatic RCT of 36 week duration with a 24 week follow‐up period. 102 children aged 2‐16 years with moderate to severe atopic eczema, unresponsive to topical treatment will be randomised (1:1) to receive methotrexate (MTX; 0.4mg/kg per week) or ciclosporin (CyA; 4mg/kg/day). The trial has co‐primary outcomes: change from baseline to 12 weeks in Objective Severity Scoring of Atopic Dermatitis (o‐SCORAD) and time to first significant flare following treatment cessation. Analysis plan: The main aims of the trial are to assess whether there is a difference in the speed of onset, effectiveness, side‐effect profile and reduction in flares post‐treatment between CyA and MTX, and, also the cost‐effectiveness of the drugs. Treatment impact on quality of life will also be examined as well as whether FLG genotype influences treatment response. In addition, the trial studies the immune‐metabolic effects of CyA and MTX. Conclusions: The TREAT trial addresses important therapeutic questions, highlighted in systematic reviews and treatment guidelines for atopic eczema. The trial design is pragmatic to reflect current clinical practice.

Item Type: Article
Uncontrolled Keywords: methotrexate,ciclosporin,atopic eczema,atopic dermatitis,eczema
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: Pure Connector
Date Deposited: 15 May 2018 09:30
Last Modified: 26 May 2020 00:02
URI: https://ueaeprints.uea.ac.uk/id/eprint/67054
DOI: 10.1111/bjd.16717

Actions (login required)

View Item View Item